CELL Stock Overview
PhenomeX Inc. operates as a functional cell biology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
PhenomeX Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.00 |
| 52 Week High | US$3.65 |
| 52 Week Low | US$0.38 |
| Beta | 0.94 |
| 1 Month Change | 2.90% |
| 3 Month Change | 116.98% |
| 1 Year Change | -68.21% |
| 3 Year Change | -98.85% |
| 5 Year Change | n/a |
| Change since IPO | -98.48% |
Recent News & Updates
Recent updates
Analyst Forecasts Just Became More Bearish On PhenomeX Inc. (NASDAQ:CELL)
May 16
PhenomeX Inc.'s (NASDAQ:CELL) Subdued P/S Might Signal An Opportunity
Apr 17Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue Forecasts
Aug 15Mehul Joshi joins Berkeley Lights as CFO
Jul 25Berkeley Lights Grows Revenue But Operating Losses Mount
Dec 09Are Investors Undervaluing Berkeley Lights, Inc. (NASDAQ:BLI) By 49%?
Nov 07Berkeley Lights: Short Seller Report Raises A Few Legitimate Questions
Sep 23Berkeley Lights: Optofluidic Technology Presents Strong Upside, May Redefine Therapeutic Development
Jun 09Berkeley Lights Q1 2021 Earnings Preview
May 10Shareholder Returns
| CELL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0.5% | -4.2% | -4.0% |
| 1Y | -68.2% | -5.1% | 24.0% |
Return vs Industry: CELL underperformed the US Life Sciences industry which returned -13.4% over the past year.
Return vs Market: CELL underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| CELL volatility | |
|---|---|
| CELL Average Weekly Movement | 40.4% |
| Life Sciences Industry Average Movement | 9.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CELL's share price has been volatile over the past 3 months.
Volatility Over Time: CELL's weekly volatility has increased from 23% to 40% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 285 | Siddhartha Kadia | phenomex.com |
PhenomeX Inc. operates as a functional cell biology company. The company enables scientists to reveal insights on cell function and obtain behavior of each cell. Its suite of tools and services offer unparalleled resolution and speed, accelerating the insights for advancing discoveries that can profoundly improve the prevention and treatment of disease.
PhenomeX Inc. Fundamentals Summary
| CELL fundamental statistics | |
|---|---|
| Market cap | US$99.63m |
| Earnings (TTM) | -US$124.53m |
| Revenue (TTM) | US$71.82m |
1.4x
P/S Ratio-0.8x
P/E RatioIs CELL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CELL income statement (TTM) | |
|---|---|
| Revenue | US$71.82m |
| Cost of Revenue | US$25.32m |
| Gross Profit | US$46.50m |
| Other Expenses | US$171.03m |
| Earnings | -US$124.53m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.25 |
| Gross Margin | 64.75% |
| Net Profit Margin | -173.40% |
| Debt/Equity Ratio | 0% |
How did CELL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/04 00:27 |
| End of Day Share Price | 2023/09/29 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PhenomeX Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Goparaju | Berenberg |
| Mark Massaro | BTIG |
| Tycho Peterson | J.P. Morgan |